[go: up one dir, main page]

CY1115687T1 - Ενωσεις για θεραπεια ανικανοτητας - Google Patents

Ενωσεις για θεραπεια ανικανοτητας

Info

Publication number
CY1115687T1
CY1115687T1 CY20141100900T CY141100900T CY1115687T1 CY 1115687 T1 CY1115687 T1 CY 1115687T1 CY 20141100900 T CY20141100900 T CY 20141100900T CY 141100900 T CY141100900 T CY 141100900T CY 1115687 T1 CY1115687 T1 CY 1115687T1
Authority
CY
Cyprus
Prior art keywords
formula
compounds
present
units
treatment
Prior art date
Application number
CY20141100900T
Other languages
English (en)
Inventor
Liu Baoshum
Original Assignee
Guangzhou Youcare Biopharmaceatics Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25740515&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1115687(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Guangzhou Youcare Biopharmaceatics Co., Ltd filed Critical Guangzhou Youcare Biopharmaceatics Co., Ltd
Publication of CY1115687T1 publication Critical patent/CY1115687T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε νέες ενώσεις του τύπου (I) οι οποίες είναι εκλεκτικοί αναστολείς φωσφοδιεστεράσης, φαρμακευτικώς αποδεκτά άλατα ή ισομερή αυτών. Η παρούσα εφεύρεση επίσης παρέχει μεθόδους για παρασκευή των ενώσεων του τύπου (I) και νέα ενδιάμεσα που ενέχονται στη συνθετική οδό των ενώσεων του τύπου (I). Οι ενώσεις του τύπου (I) της παρούσης εφεύρεσης είναι όχι μόνο πολύ αποτελεσματικές για τη θεραπεία ασθενειών ανικανότητας, όπως στυτικής δυσλειτουργίας του άρρενος, αλλά επίσης έχουν τέτοια χαρακτηριστικά όπως μακράς διάρκειας ιατρική αποτελεσματικότητα και μικρότερη τοξικότητα.
CY20141100900T 2001-06-29 2014-10-31 Ενωσεις για θεραπεια ανικανοτητας CY1115687T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN01129691 2001-06-29
CN02100198A CN1127506C (zh) 2001-06-29 2002-01-18 一种治疗阳痿的新化合物
EP02754139.0A EP1400522B1 (en) 2001-06-29 2002-06-21 Compounds for treating impotence

Publications (1)

Publication Number Publication Date
CY1115687T1 true CY1115687T1 (el) 2017-01-25

Family

ID=25740515

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100900T CY1115687T1 (el) 2001-06-29 2014-10-31 Ενωσεις για θεραπεια ανικανοτητας

Country Status (18)

Country Link
US (1) US6960592B2 (el)
EP (1) EP1400522B1 (el)
JP (1) JP4469174B2 (el)
KR (1) KR100878739B1 (el)
CN (1) CN1127506C (el)
AU (1) AU2002323774B2 (el)
BR (1) BRPI0211025B8 (el)
CA (1) CA2451990C (el)
CY (1) CY1115687T1 (el)
DK (1) DK1400522T3 (el)
ES (1) ES2519441T3 (el)
IL (1) IL159386A0 (el)
MA (1) MA26117A1 (el)
MX (1) MXPA03011929A (el)
NZ (1) NZ530548A (el)
PT (1) PT1400522E (el)
RU (1) RU2279433C2 (el)
WO (1) WO2003016313A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100360531C (zh) * 2003-12-18 2008-01-09 中国人民解放军军事医学科学院放射与辐射医学研究所 用于预防或治疗阳萎和性冷淡的新吡唑并嘧啶类化合物
EP2024369A4 (en) * 2006-06-05 2010-10-27 Matrix Lab Ltd NEW PROCESS FOR THE PREPARATION OF SILDENAFIL CITRATE
CN101914100B (zh) * 2010-04-13 2013-01-30 漆又毛 苯磺酰基二甲基哌嗪衍生物及制备方法
CN101891747B (zh) * 2010-07-02 2012-04-25 张南 抑制5型磷酸二酯酶的化合物及制备方法
CN109970744A (zh) * 2019-04-10 2019-07-05 重庆康刻尔制药有限公司 一种枸橼酸西地那非中间体的合成方法
CN112745323B (zh) * 2020-12-30 2021-10-29 北京悦康科创医药科技股份有限公司 枸橼酸爱地那非晶型h及其制备方法和用途
CN113350301B (zh) * 2021-06-03 2022-10-04 刘宝顺 一种治疗阳痿的新化合物中药蜜丸
US20250041309A1 (en) 2021-12-14 2025-02-06 Zhenao Jinyinhua Pharmaceutical Use of aildenafil or salt thereof in preparation of medicine for preventing or treating ischemic brain damage
KR102580664B1 (ko) 2023-01-25 2023-09-21 (주)나인팩토리커뮤니케이션 남성 성기에 부종감 및 온열감을 주고 혈행을 개선하는 피부 외용제 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
GB9311920D0 (en) * 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US6200980B1 (en) * 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
GB9612514D0 (en) * 1996-06-14 1996-08-14 Pfizer Ltd Novel process
AU4501199A (en) * 1998-06-03 1999-12-20 Almirall Prodesfarma S.A. 8-phenylxanthine derivatives and their use as phosphodiesterase inhibitors
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.

Also Published As

Publication number Publication date
RU2004102513A (ru) 2005-03-27
US6960592B2 (en) 2005-11-01
JP2005500381A (ja) 2005-01-06
CA2451990C (en) 2008-06-17
WO2003016313A1 (fr) 2003-02-27
JP4469174B2 (ja) 2010-05-26
DK1400522T3 (da) 2014-11-10
AU2002323774B2 (en) 2007-10-25
PT1400522E (pt) 2014-10-30
KR20040010779A (ko) 2004-01-31
MA26117A1 (fr) 2004-04-01
KR100878739B1 (ko) 2009-01-14
EP1400522B1 (en) 2014-08-06
RU2279433C2 (ru) 2006-07-10
BR0211025A (pt) 2004-10-19
EP1400522A4 (en) 2006-04-05
CN1127506C (zh) 2003-11-12
MXPA03011929A (es) 2005-03-07
EP1400522A1 (en) 2004-03-24
NZ530548A (en) 2005-04-29
BRPI0211025B8 (pt) 2021-05-25
BRPI0211025B1 (pt) 2016-03-01
US20040152709A1 (en) 2004-08-05
CA2451990A1 (en) 2003-02-27
CN1393444A (zh) 2003-01-29
IL159386A0 (en) 2004-06-01
ES2519441T3 (es) 2014-11-07

Similar Documents

Publication Publication Date Title
CY1115687T1 (el) Ενωσεις για θεραπεια ανικανοτητας
CY1108041T1 (el) Αναστολεις της rho-κινασης
CY1107475T1 (el) Αναστολεις ρο-κινασης
EA200300788A1 (ru) Производные замещенных алкиламинов и их применение
CY1105301T1 (el) Αρυλοσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
CY1107747T1 (el) Υποκατεστημενα τετρακυκλικα παραγωγα πυρρολοκινολονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
TR200201505T2 (tr) Terapötik maddeler olarak pirazolopirimidinler
EA200100411A1 (ru) Замещенные 3-цианохинолины в качестве ингибиторов протеинтирозинкиназ
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
ATE381557T1 (de) Rho-kinase inhibitoren
BG66085B1 (bg) Фенилаланинови производни
EA200300527A1 (ru) Новые способы лечения синдрома "усталых ног"
ECSP044992A (es) Inhibidores de la alquín-aril fosfodiesterasa-4
NI200600319A (es) Antagonistas de ccr2 de sal cuaternaria
ATE441654T1 (de) Edg-rezeptoragonisten
HUP0301573A2 (hu) Szubsztituált arilpirazinok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
CY1106645T1 (el) Παραγωγα 1,2,4 τριαμινοβενζολης χρησιμα για τη θεραπευτικη αντιμετωπιση διαταραχων του κεντρικου νευρικου συστηματος
EA200600071A1 (ru) Производные n-фенилпиперазина и способы профилактики или лечения заболеваний, связанных с 5ht-рецептором
PA8527401A1 (es) 7-oxo-piridopirimidinas (ii)
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
IS2387B (is) Æxliseyðandi efni
EP1453506A4 (en) Topoisomerase GIFT FUNDS
UY27034A1 (es) Derivados de pirimidina
CY1105529T1 (el) Αντικατεστημενα με θειοφαινιο παραγωγα αμυνης σαν glyt-1 αναστολεις
PE20030125A1 (es) PIRIDO[1,2-c]PIRIMIDINA COMO AGENTES ANTIBACTERIANOS